חזרה לתוצאות החיפוש

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Oligometastatic Prostate Cancer (OMPC)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Highlands Oncology Group, Fayetteville, Arkansas, United States

    Contact: Study coordinator (Tina Patrick) · tpatrick@hogonc.com · +1 479 878 7098
    Contact: Principal Investigator (Joseph Thaddeus Beck)

  • VA Greater LA Healthcare System, Los Angeles, California, United States

    Contact: Study coordinator (Samantha Tran) · Samantha.Tran@va.gov · 310-478-3711
    Contact: Principal Investigator (Matthew Rettig)

  • VA Palo Alto Health Care System, Palo Alto, California, United States

    Contact: Study coordinator (Niko Del Mar) · niko.delmar@va.gov · 650-493-5000
    Contact: Principal Investigator (Minal Vasanawala)

  • Stanford University, Palo Alto, California, United States

    Contact: Study coordinator (Camellia Djebroun) · cdjebrou@stanford.edu · 605-498-6000
    Contact: Principal Investigator (Mallika Marar)

  • UCSF, San Francisco, California, United States

    Contact: Study coordinator (Francim Aguilar) · francim.aguilar@ucsf.edu · 415-514-6241
    Contact: Principal Investigator (Steven Seyedin)

  • Rocky Mountain Cancer Centers, Denver, Colorado, United States

    Contact: Study coordinator (Jennifer Hege) · jennifer.hege@usoncology.com · 303-338-4876
    Contact: Principal Investigator (Allen Cohn)

  • Cancer Specialists of North Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Bhaloo Desai) · Bhaloo.Desai@CSNF.us
    Contact: Principal Investigator (Richard Cassidy)

  • Woodlands Medical Specialists, Pensacola, Florida, United States

    Contact: Study coordinator (Jacqueline Martin) · jacqueline.martin@woodlandsmed.com
    Contact: Principal Investigator (Michael Poiesz)

  • Piedmont Healthcare, Atlanta, Georgia, United States

    Contact: Study coordinator (Sharon Joseph)
    Contact: Principal Investigator (Adam Nowlan)

  • University of Chicago, Chicago, Illinois, United States

    Contact: Study coordinator (Ashley Page) · apage99@bsd.uchicago.edu · 773-702-8582
    Contact: Principal Investigator (Mohammed Atiq)

  • The Cancer Institute of Alexian Brothers, Elk Grove, Illinois, United States

    Contact: Study coordinator (Khalada Ahmad) · khalada.ahmad@ascension.org

  • Unity Point Clinic, Des Moines, Iowa, United States

    Contact: Study coordinator (Missy Stravers) · mstravers@iora.org
    Contact: Principal Investigator (Mark Kellerman)

  • University of Kansas Hospital, Kansas City, Kansas, United States

    Contact: Study coordinator (Daniel Rivera) · drivera3@kumc.edu
    Contact: Principal Investigator (Xinglei Shen)

  • Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States

    Contact: Study coordinator (Courtney Hill) · chill@marybird.com · 225-215-1353
    Contact: Principal Investigator (Victor Lin)

  • East Jefferson Hospital, Metairie, Louisiana, United States

    Contact: Study coordinator (Alexandra Lieberman) · alexandra.lieberman@lcmchealth.org
    Contact: Principal Investigator (Alton Oliver Sartor)

  • University of Maryland Medical Ctr, Baltimore, Maryland, United States

    Contact: Study coordinator (Dawn Barth) · Dawn.Barth@umm.edu · 410-328-8667
    Contact: Principal Investigator (Arif Hussain)

  • Johns Hopkins Kimmel Com Cancer Ctr, Baltimore, Maryland, United States

    Contact: Study coordinator (Dana Kaplan) · dkaplin1@jhmi.edu
    Contact: Principal Investigator (Ana Kiess)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Sinead Christensen) · smchristensen@bwh.harvard.edu
    Contact: Principal Investigator (Mai Anh Huynh)

  • Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States

    Contact: Study coordinator (Stephen Duggan) · sduggan@bidmc.harvard.edu
    Contact: Principal Investigator (David J Einstein)

  • BAMF Health, Grand Rapids, Michigan, United States

    Contact: Study coordinator (Kamara Kam Bailey) · kam.bailey@bamfhealth.com
    Contact: Principal Investigator (Brandon Mancini)

  • Profound Research LLC, Royal Oak, Michigan, United States

  • William Beaumont Hospital, Royal Oak, Michigan, United States

    Contact: Study coordinator (Jennifer Murray) · jennifer.murray@beaumont.org · 248-551-6485
    Contact: Principal Investigator (Andrew Thompson)

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Takeru Walleser) · Walleser.Takeru@mayo.edu · 507-538-2155
    Contact: Principal Investigator (Ryan Phillips)

  • VA St Louis Health Care System, St Louis, Missouri, United States

    Contact: Study coordinator (Janine Kampelman) · janine.kampelman@va.gov · 314-652-4100
    Contact: Principal Investigator (Medhat Osman)

  • Wash U School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Collin Welch) · c.welch@wustl.edu
    Contact: Principal Investigator (Hiram Gay)

  • The Urology Center PC DBA UroHealth Partners, Omaha, Nebraska, United States

    Contact: Study coordinator (Amy Nelson) · anelson@urohealthpartners.com
    Contact: Principal Investigator (Andrew Trainer)

  • Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

    Contact: Study coordinator (Viktoria Matessi) · matessiv@mskcc.org · 212-639-3854
    Contact: Principal Investigator (Daniel Gorovets)

  • Associated Med Professionals of NY, Syracuse, New York, United States

    Contact: Study coordinator (Alex Bart) · alex.bart@ampofny.com
    Contact: Principal Investigator (Steven Finkelstein)

  • Montefiore Hospital, The Bronx, New York, United States

    Contact: Study coordinator (Darciann O Sullivan) · dosulli@montefiore.org · 267-455-2717
    Contact: Principal Investigator (Benjamin A Gartrell)

  • East Carolina University, Greenville, North Carolina, United States

    Contact: Study coordinator (Kayleigh Nunley) · nunleyk16@ecu.edu · 252-744-0456
    Contact: Principal Investigator (Andrew Ju)

  • Dayton Physicians, Kettering, Ohio, United States

    Contact: Study coordinator (Lynette Tipton) · Lynette.Tipton@StatResearch.com · 937-771-2287
    Contact: Principal Investigator (Trevor Bluemel)

  • Oregon Urology Institute, Springfield, Oregon, United States

    Contact: Study coordinator (Cordell Chase) · cchase@oregonurology.com · 541-284-5508
    Contact: Principal Investigator (Bryan Mehlhaff)

  • Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

    Contact: Study coordinator (Rebecca Floyd) · rebecca.floyd@startresearch.com · 843-839-1679
    Contact: Principal Investigator (Neal D Shore)

  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Laura Diedrich) · laura.diedrich@vumc.org
    Contact: Principal Investigator (Kerry Schaffer)

  • Univ of Texas Southwest Med Center, Dallas, Texas, United States

    Contact: Study coordinator (Amy Rowell) · Amy.Rowell@UTSouthwestern.edu · 214-645-5905
    Contact: Principal Investigator (Kevin Courtney)

  • Rio Grande Urology, El Paso, Texas, United States

    Contact: Study coordinator (Joshua Ortiz-Guzman) · jortiz@riograndeurology.com
    Contact: Principal Investigator (Jameson T Mendel)

  • Virginia Oncology Associates, Norfolk, Virginia, United States

    Contact: Study coordinator (Amber Ingram) · amber.ingram@usoncology.com · 757-466-8683
    Contact: Principal Investigator (Mark Fleming)

  • Blue Ridge Cancer Center, Wytheville, Virginia, United States

    Contact: Study coordinator (Dana Selvia) · dana.selvia@usoncology.com
    Contact: Principal Investigator (David Buck)

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Herston, Queensland, Australia

  • Novartis Investigative Site, Adelaide, South Australia, Australia

  • Novartis Investigative Site, Malvern, Victoria, Australia

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Aalst, Belgium

  • Novartis Investigative Site, Ghent, Belgium

  • Novartis Investigative Site, Wilrijk, Belgium

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Calgary, Alberta, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, London, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Ostrava, Poruba, Czechia

  • Novartis Investigative Site, Olomouc, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France

  • Novartis Investigative Site, Angers, France

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Bron, France

  • Novartis Investigative Site, Clermont-Ferrand, France

  • Novartis Investigative Site, Rouen, France

  • Novartis Investigative Site, Saint-Herblain, France

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Aachen, Germany

  • Novartis Investigative Site, Augsburg, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Rostock, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Beersheba, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Cona, FE, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Rozzano, MI, Italy

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Negrar, VR, Italy

  • Novartis Investigative Site, Milan, Italy

  • Novartis Investigative Site, Kashiwa, Chiba, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Ishikawa, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Mexico City, Mexico City, Mexico

  • Novartis Investigative Site, Huxquilucan, Mexico

  • Novartis Investigative Site, Amsterdam, Netherlands

  • VA Caribbean Healthcare System, San Juan, Puerto Rico

    Contact: Study coordinator (Sara Fuentes-Medina) · Sara.Fuentes-Medina@va.gov · +17876417582#10393
    Contact: Principal Investigator (Bartolo Santiago-Delgado)

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Bratislava, Slovakia

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Nitra, Slovakia

  • Novartis Investigative Site, Trenčín, Slovakia

  • Novartis Investigative Site, Granada, Andalusia, Spain

  • Novartis Investigative Site, Barcelona, Catalonia, Spain

  • Novartis Investigative Site, El Palmar, Murcia, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Seville, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Lucerne, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Bristol, Avon, United Kingdom

  • Novartis Investigative Site, Guildford, Surrey, United Kingdom

  • Novartis Investigative Site, Sutton, Surrey, United Kingdom

  • Novartis Investigative Site, Coventry, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)